financetom
Business
financetom
/
Business
/
Update: Fabrinet Fiscal Q4 Non-GAAP EPS, Sales Jump; Repurchases Expanded; Shares Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Fabrinet Fiscal Q4 Non-GAAP EPS, Sales Jump; Repurchases Expanded; Shares Rise
Aug 20, 2024 9:54 AM

12:23 PM EDT, 08/20/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.)

Fabrinet ( FN ) shares were up over 18% in recent Tuesday trading after the company overnight reported higher fiscal Q4 earnings and sales, beating expectations, and unveiled an expanded stock buyback program.

The company reported fiscal Q4 non-GAAP earnings late Monday of $2.41 per diluted share, up from $1.86 a year earlier.

Analysts polled by Capital IQ expected $2.24.

Revenue for the quarter ended June 28 was $753.3 million, up from $655.9 million a year earlier.

Analysts surveyed by Capital IQ expected $732.6 million.

The company said it expects fiscal Q1 non-GAAP EPS between $2.33 and $2.40 and revenue between $760 million and $780 million.

Analysts polled by Capital IQ expect normalized EPS of $2.26 on revenue of $751.9 million.

Fabrinet ( FN ) said its board approved an expansion of the company's share buyback plan, authorizing the repurchase of up to an additional $139.5 million of shares. The move increases the total authorization under its share buyback program to $434.3 million, with $200 million remaining, the company said.

Price: 274.10, Change: +42.55, Percent Change: +18.37

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck to Acquire B-Cell Depletion Therapy From Curon Biopharmaceutical
Merck to Acquire B-Cell Depletion Therapy From Curon Biopharmaceutical
Aug 9, 2024
07:24 AM EDT, 08/09/2024 (MT Newswires) -- Merck ( MRK ) said Friday it has agreed to acquire full global rights to CN201, an investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from Curon Biopharmaceutical. Under the terms of the agreement, Merck ( MRK ) will pay $700 million upfront in cash and Curon will be eligible...
Cineplex Swings to Q2 Loss as Revenue, Theater Attendance Drop
Cineplex Swings to Q2 Loss as Revenue, Theater Attendance Drop
Aug 9, 2024
07:31 AM EDT, 08/09/2024 (MT Newswires) -- Cineplex ( CPXGF ) said Friday that it swung to a net loss in the second quarter following a 25% drop in revenue. The movie theater operator booked a net loss of $21.4 million, or $0.33 per share, compared to a net profit of $176.5 million, or $2.79 per share. Revenue dropped to...
Evercore hires Goldman banker Kamo for private equity dealmaking, sources say
Evercore hires Goldman banker Kamo for private equity dealmaking, sources say
Aug 9, 2024
NEW YORK, Aug 9 (Reuters) - Investment bank Evercore ( EVR ) has hired a top Goldman Sachs ( GS ) dealmaker as a senior managing director to help drive its coverage of private equity firms and alternative asset managers, people familiar with the matter said on Friday. David Kamo, who was named global head of dealmaking for financial sponsors...
Evolent Health Q2 Adjusted Earnings, Revenue Climb; Lifts Lower End of FY Revenue Guidance
Evolent Health Q2 Adjusted Earnings, Revenue Climb; Lifts Lower End of FY Revenue Guidance
Aug 9, 2024
07:16 AM EDT, 08/09/2024 (MT Newswires) -- Evolent Health ( EVH ) reported Q2 adjusted earnings Friday of $0.30 per share, up from $0.14 a year earlier. Analysts polled by Capital IQ expected $0.25. Revenue for the quarter ended June 30 was $647.1 million, up from $469.1 million a year earlier. Analysts polled by Capital IQ expected $636.4 million. Evolent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved